WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb and PsiOxus Therapeutics announce immuno-oncology clinical collaboration
30 June 2016
Ready. Raise. Rise. Campaign
06 May 2016
Bristol-Myers Squibb reports first quarter financial results
28 April 2016
Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
23 March 2016
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies
07 March 2016
Bristol-Myers Squibb completes previously announced sale of its HIV R&D portfolio to ViiV Healthcare
22 February 2016
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement
16 February 2016
Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening
01 February 2016
Bristol-Myers Squibb to sell its HIV R&D portfolio to ViiV Healthcare
18 December 2015
Bristol-Myers Squibb and UCLA enter into a collaboration agreement
14 December 2015
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M
01 December 2015
Bristol-Myers Squibb to acquire Cardioxyl Pharmaceuticals, Inc.
02 November 2015
Bristol-Myers Squibb reports third quarter financial results
27 October 2015
Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC)
12 October 2015
Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement
25 September 2015
Bristol-Myers Squibb Employees cycle nearly 2,900 miles to raise money for cancer research
10 September 2015
Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
04 August 2015
Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
16 April 2015
Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases
24 March 2015
FDA approves Opdivo (nivolumab) for the treatment of patients with previously treated metastatic squamous non-small cell lung cancer
05 March 2015
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Research & Development
Candidate found to inhibit malignant melanoma growth
A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA approves first over-the-counter naloxone nasal spray
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
You are here:
Home
Bristol-Myers Squibb
Bristol-Myers Squibb and Boston Medical Center announce research collaboration to investigate markers of immuno-oncology response and resistance